Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2375800 | 0.86 | TAAR1 (0.46) | TAAR1SLC6A2CYP2A6 | |
| SCHEMBL30556750 | 0.84 | IDO1 (0.46) | IDO1TAAR1CYP1A2CYP2A6ACHE | |
| SCHEMBL29202576 | 0.82 | HPGD (0.46) | IDO1TAAR1SLC6A2CYP1A2CYP2A6 | |
| SCHEMBL29018029 | 0.82 | IDO1 (0.44) | IDO1TAAR1CYP1A2CYP2A6ACHE | |
| SCHEMBL13862138 | 0.82 | HPGD (0.46) | IDO1TAAR1SLC6A2CYP1A2CYP2A6 | |
| SCHEMBL4376445 | 0.82 | HPGD (0.46) | IDO1TAAR1SLC6A2CYP1A2CYP2A6 | |
| SCHEMBL24785864 | 0.80 | NR3C2 (0.46) | IDO1TAAR1CYP1A2CYP2A6PSMB5 | |
| SCHEMBL11144044 | 0.80 | IDO1 (0.42) | IDO1TAAR1CYP1A2CYP2A6ACHE | |
| SCHEMBL115445 | 0.80 | TRPA1 (0.45) | IDO1TAAR1SLC6A2CYP1A2CYP2A6 | |
| SCHEMBL28288968 | 0.80 | IDO1 (0.42) | IDO1TAAR1CYP1A2CYP2A6ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367662-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-02-05 | — | — | US | disclosed |
| US-8367662-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-02-05 | — | — | US | disclosed |
| US-20100210641-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-08-19 | — | — | US | disclosed |
| US-20100210641-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-08-19 | — | — | US | disclosed |
| EP-0383995-B1 | Aromatic thermosetting resins and preparation thereof | SUMIKIN CHEMICAL (JP) | 1997-10-15 | — | — | EP | disclosed |
| US-5017683-A | Organic acid catalyst | SUMIKIN CHEMICAL CO., LTD. (JP) | 1991-05-21 | — | — | US | disclosed |
| EP-0383995-A2 | Aromatic thermosetting resins and preparation thereof | SUMIKIN CHEMICAL CO., LTD. (JP) | 1990-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210641-A1 | Organic Compounds | ALK, ACVR1, ACVRL1 | IDO1 3471/4885TAAR1 609/4885SLC6A2 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.